Utility-based optimization of phase II/III programs

DOI10.1002/SIM.6624MaRDI QIDQ6966077zbMATH OpenFDO

Authors Marietta Kirchner, Meinhard Kieser, Heiko Götte

Publication date 30 June 2025

Published in Statistics in Medicine (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/SIM.6624

zbMATH Keywords

drug developmentexpected utilityoptimizationprobability of successprogram-wise planning

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk
• Accounting for Variability in Sample Size Estimation with Applications to Nonadherence and Estimation of Variance and Effect Size
• Bayesian Optimal Design for Phase II Screening Trials
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• Uncertain Judgements: Eliciting Experts' Probabilities

This page was built for publication: Utility-based optimization of phase II/III programs

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6966077)